Grape Seed Extract
Phase 1Small molecule
Grape Seed Extract is one of 24 small molecule programs targeting Diastolic Heart Failure. It is currently in Phase 1.
1
Indications
6
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Diastolic Heart Failure
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaApproved
Letairis
GileadApproved
Aldactone
PfizerApproved
Farxiga
AstraZenecaApproved
Klor-Con
NovartisApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Tracleer
Johnson & JohnsonPhase 3
Fimasartan
Boryung Pharmaceutical Co., LtdApproved
Viagra
VViatris Specialty LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Cancer1 trial
Diastolic Heart Failure1 trial
Efficacy1 trial
Medication1 trial
Revascularization of Young Immature Permenant Teeth Using Different Types of Intra Canal Medication
Not yet recruiting·—·N/A·NCT07236567·45 enrolled
1 more indication
Dentin Hypersensitivity1 trial
Grape Seed Extract VS Low Level Laser Therapy for Dentin Hypersensitivity
Unknown status·—·N/A·NCT05927831·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Grape Seed Extract. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details